VEGFA and neoplasm: thus they concluded that topical application of bevacizumab inhibits both inflammation-induced angiogenesis and lymph angiogenesis in the cornea.14 The findings in his study suggests an important role of VEGF-A in corneal lymph angiogenesis.14 He also concluded that Bevacizumab may be useful in preventing immune rejections after penetrating keratoplasty or tumor metastasis via lymphatic vessels.